GLP-1 and amylin agonism combined in a single molecule, not a two-drug combination. Structurally it is Unimolecular GLP-1 + amylin receptor agonist (peptide).

How strong is the evidence for Amycretin?

PeptideHormone grades Amycretin at the "Investigational" evidence tier — it is under active human investigation — promising, but not yet settled. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.

What is the half-life of Amycretin?

The reported circulating half-life of Amycretin is ~days (weekly SC dosing).

Amycretin

GLP-1 and amylin agonism combined in a single molecule, not a two-drug combination.

AnalogInvestigationalBased on AmylinCompare with IAPP Compare lineage

Two hormones written into one chain rather than mixed in one syringe — the difference between a combination and a molecule.

Identity

Class: Unimolecular GLP-1 + amylin receptor agonist (peptide)
Source: Synthetic; engineered unimolecular dual agonist
Receptor: GLP-1 receptor + amylin receptors

Key properties

Evidence floorClinicalREF1CLIN1

Molecular weight

≈ 7,900 Da

REF

Half-life (native)

~days (weekly SC dosing)

CLIN

Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.

Mechanism

Amycretin is a single molecule that agonizes both the GLP-1 receptor and amylin receptors — two appetite-suppressing pathways combined in one agent rather than as a two-drug combination. Developed in both subcutaneous and oral forms, it is an early-stage attempt to capture the additive GLP-1-plus-amylin effect from a single molecule. It is investigational.

One peptide, two receptor arms — the same pair CagriSema plays with two separate molecules. Amycretin is the unimolecular bet, with an oral form chasing convenience alongside the injection.

In depth

CagriSema proved the GLP-1-plus-amylin bet with two molecules in two pens. Amycretin asks the obvious next question: why two? It is a single peptide engineered to agonize both the GLP-1 receptor and the amylin receptors — the same two satiety pathways cagrilintide and semaglutide play separately, collapsed into one molecule. If the stack works as a combination, the argument runs, it should work unimolecular, with one injection, one pharmacokinetic profile, one manufacturing line.

The ambition does not stop at the syringe. Amycretin is being developed in both subcutaneous and oral forms — the oral version riding the absorption-enhancer playbook that made Rybelsus possible, the injectable aiming for weekly dosing. A dual agonist you could take as a daily pill would sit at the far end of the convenience spectrum from where this class began: a twice-daily injection derived from lizard venom.

What exists so far is early. First-in-human and phase 1b/2a data have shown the class-typical weight-loss trajectory and a tolerability profile consistent with the GLP-1 family, but the sample sizes are small and the follow-up short. Amycretin is a promising sketch of where unimolecular multi-agonism goes next — not yet the evidence that it gets there.

Reference notes

Combines GLP-1 and amylin agonism in one molecule — the single-agent counterpart to the CagriSema combination.
Under investigation in both injectable and oral formulations.
Investigational and early-stage — first-in-human and phase 1b/2a data only.

Common questions

What is Amycretin?: GLP-1 and amylin agonism combined in a single molecule, not a two-drug combination. Structurally it is Unimolecular GLP-1 + amylin receptor agonist (peptide).
How does Amycretin work?: Amycretin is a single molecule that agonizes both the GLP-1 receptor and amylin receptors — two appetite-suppressing pathways combined in one agent rather than as a two-drug combination. Developed in both subcutaneous and oral forms, it is an early-stage attempt to capture the additive GLP-1-plus-amylin effect from a single molecule. It is investigational.
How strong is the evidence for Amycretin?: PeptideHormone grades Amycretin at the "Investigational" evidence tier — it is under active human investigation — promising, but not yet settled. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.
What is the half-life of Amycretin?: The reported circulating half-life of Amycretin is ~days (weekly SC dosing).

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

1.Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial · Lancet (London, England), 2025 · PMID 40550229
2.Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study · Lancet (London, England), 2025 · PMID 40550231

External references

Amycretin in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.